Smith Margaret M, Melrose James
Raymond Purves Laboratory, Institute of Bone and Joint Research, Kolling Institute of Medical Research, Faculty of Health and Science, University of Sydney, Royal North Shore Hospital, St. Leonards, NSW 2065, Australia.
Arthropharm Pty Ltd., Bondi Junction, NSW 2022, Australia.
Int J Mol Sci. 2024 Feb 29;25(5):2825. doi: 10.3390/ijms25052825.
This study has reviewed the many roles of lumican as a biomarker of tissue pathology in health and disease. Lumican is a structure regulatory proteoglycan of collagen-rich tissues, with cell instructive properties through interactions with a number of cell surface receptors in tissue repair, thereby regulating cell proliferation, differentiation, inflammation and the innate and humoral immune systems to combat infection. The exponential increase in publications in the last decade dealing with lumican testify to its role as a pleiotropic biomarker regulatory protein. Recent findings show lumican has novel roles as a biomarker of the hypercoagulative state that occurs in SARS CoV-2 infections; thus, it may also prove useful in the delineation of the complex tissue changes that characterize COVID-19 disease. Lumican may be useful as a prognostic and diagnostic biomarker of long COVID disease and its sequelae.
本研究回顾了核心蛋白聚糖作为健康和疾病中组织病理学生物标志物的多种作用。核心蛋白聚糖是富含胶原蛋白组织的结构调节蛋白聚糖,通过与组织修复中的多种细胞表面受体相互作用具有细胞指导特性,从而调节细胞增殖、分化、炎症以及先天性和体液免疫系统以对抗感染。过去十年中关于核心蛋白聚糖的出版物呈指数增长,证明了其作为多效性生物标志物调节蛋白的作用。最近的研究结果表明,核心蛋白聚糖在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染中出现的高凝状态生物标志物方面具有新的作用;因此,它在描绘以2019冠状病毒病(COVID-19)为特征的复杂组织变化方面可能也很有用。核心蛋白聚糖可能作为长期新冠疾病及其后遗症的预后和诊断生物标志物。